Longitudinal proteomic profiling provides insights into host response and proteome dynamics in COVID‐19 progression

Lee, Jee‐Soo; Han, Dohyun; Kim, So Yeon; Hong, Ki Ho; Jang, Myoung‐jin; Kim, Man Jin; Kim, Young‐gon; Park, Jae Hyeon; Cho, Sung Im; Park, Wan Beom; Lee, Kyung Bok; Shin, Ho Seob; Oh, Hyeon Sae; Kim, Taek Soo; Park, Sung Sup; Seong, Moon‐Woo

In managing patients with coronavirus disease 2019 (COVID‐19), early identification of those at high risk and real‐time monitoring of disease progression to severe COVID‐19 is a major challenge. We aimed to identify potential early prognostic protein markers and to expand understanding of proteome dynamics during clinical progression of the disease. We performed in‐depth proteome profiling on 137 sera, longitudinally collected from 25 patients with COVID‐19 (non‐severe patients, n = 13; patients who progressed to severe COVID‐19, n = 12). We identified 11 potential biomarkers, including the novel markers IGLV3‐19 and BNC2, as early potential prognostic indicators of severe COVID‐19. These potential biomarkers are mainly involved in biological processes associated with humoral immune response, interferon signalling, acute phase response, lipid metabolism, and platelet degranulation. We further revealed that the longitudinal changes of 40 proteins persistently increased or decreased as the disease progressed to severe COVID‐19. These 40 potential biomarkers could effectively reflect the clinical progression of the disease. Our findings provide some new insights into host response to SARS‐CoV‐2 infection, which are valuable for understanding of COVID‐19 disease progression. This study also identified potential biomarkers that could be further validated, which may support better predicting and monitoring progression to severe COVID‐19.